Omvoh
Omvoh ingredients
| Active ingredient | Strength |
|---|---|
| Mirikizumab | 20 mg/mL, 100 mg/mL |
What Omvoh is used for
The FDA lists the approved uses on the official label (below). In the EU, mirikizumab is approved as Omvoh for:
Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Omvoh
- Generic name
- Mirikizumab-mrkz
- Made by
- Eli Lilly and Company
- Forms
- Injection, Solution, Kit
- Given
- Intravenous, Subcutaneous
- Drug class
- Interleukin-23 Antagonist
- FDA approval
- Biologic licence (BLA) BLA761279
- On the US market since
- 2023
Official information
- Omvoh prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Mirikizumab-mrkz)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Omvoh?
Omvoh (Mirikizumab-mrkz) is a specialist medicine made by Eli Lilly and Company, approved by the US FDA.
What are the ingredients of Omvoh?
Omvoh contains Mirikizumab (20 mg/mL, 100 mg/mL).
Is Omvoh approved in Europe?
The same active substance is approved in the EU as Omvoh.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA